This is the authors' abstract. We don't add key points for this paper.
Emerging infectious diseases and late-stage cancers demand rapid, sensitive, and deployable diagnostics. Here, we present HOMEBRED (highly sensitive & specific omnipresent multipurpose endonuclease based reliable detection), a CRISPR-based platform capable of detecting human and animal pathogens (viral/bacterial, RNA/DNA) alongside oncogenic transcripts. HOMEBRED advances veterinary medicine by integrating CaSilico, an automated tool that designs crRNAs by identifying conserved, mutant-resistant regions across pathogenic genomes. By combining CaSilico with extraction-free processing, the platform achieved field-ready FMDV (foot-and-mouth disease virus) detection with a visual readout using only a handheld blue light. Furthermore, HOMEBRED's dual-crRNA architecture differentiated Brucella vaccine strains from field isolates, overcoming long-standing DIVA (differentiating infected from vaccinated animals) limitations to prevent unnecessary culling of high-breeding-value livestock. In oncology, HOMEBRED distinguished BCR-ABL1 transcripts, establishing a foundation for early diagnosis and personalized therapy. Matching gold-standard PCR sensitivity with reduced complexity and cost, HOMEBRED offers a versatile, portable solution for precision diagnostics in point-of-care settings.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Asadbeigi et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: